Although it effectively inhibits the BCR-ABL kinase activity and improves the survival of CML patients, imatinib does not appear to lead to a cure of the disease, because patients in complete cytogenetic remission after imatinib treatment still contain BCR-ABL-expressing leukemia cells. The gene discussed is ABL1; the disease is leukemia.